NuCana PLC Sponsored ADR (NCNA) Receiving Somewhat Favorable News Coverage, Study Finds

News articles about NuCana PLC Sponsored ADR (NASDAQ:NCNA) have been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. NuCana PLC Sponsored ADR earned a media sentiment score of 0.11 on Accern’s scale. Accern also gave headlines about the company an impact score of 45.8510993000716 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

NuCana PLC Sponsored ADR (NCNA) opened at $11.31 on Friday. NuCana PLC Sponsored ADR has a twelve month low of $9.64 and a twelve month high of $19.95.

A number of analysts recently commented on the company. Cowen and Company initiated coverage on NuCana PLC Sponsored ADR in a research note on Monday, October 23rd. They issued an “outperform” rating for the company. William Blair initiated coverage on NuCana PLC Sponsored ADR in a report on Monday, October 23rd. They issued an “outperform” rating for the company. Jefferies Group LLC initiated coverage on NuCana PLC Sponsored ADR in a report on Monday, October 23rd. They issued a “buy” rating and a $25.00 price objective for the company. Finally, Citigroup Inc. initiated coverage on NuCana PLC Sponsored ADR in a report on Monday, October 23rd. They issued a “buy” rating and a $23.00 price objective for the company.

ILLEGAL ACTIVITY WARNING: This piece was posted by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be read at https://sportsperspectives.com/2017/11/19/nucana-plc-sponsored-adr-ncna-receiving-somewhat-favorable-news-coverage-study-finds.html.

About NuCana PLC Sponsored ADR

NuCana PLC is a clinical-stage biopharmaceutical company. The Company is focused on improving treatment outcomes for cancer patients by applying its phosphoramidate chemistry technology. The Company utilizes its ProTide technology to develop medicines to overcome cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells.

Receive News & Ratings for NuCana PLC Sponsored ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuCana PLC Sponsored ADR and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply